Section Arrow
Quote
KROS.NASDAQ
- Keros Therapeutics
Quotes are at least 15-min delayed:2025/09/04 23:07 EDT
Regular Hours
Last
 15.55
-0.21 (-1.33%)
Day High 
15.73 
Prev. Close
15.76 
1-M High
16.065 
Volume 
203.31K 
Bid
15.55
Ask
15.58
Day Low
15.38 
Open
15.73 
1-M Low
13.1282 
Market Cap 
640.10M 
Currency USD 
P/E 49.25 
%Yield -- 
10-SMA 15.21 
20-SMA 14.63 
50-SMA 14.29 
52-W High 72.37 
52-W Low 9.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.32/-5.01
Enterprise Value
656.98M
Balance Sheet
Book Value Per Share
17.40
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
3.55M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PPBTPurple Biotech Ltd0.78-0.64-45.07%0PE
ADAPAdaptimmune Therapeutics plc0.051-0.0016-3.04%-- 
NBYNovaBay Pharmaceuticals4.22+1.54+57.46%1.14PE
ETHZETHZilla Corporation2.42-0.1-3.97%-- 
RXRXRecursion Pharmaceuticals4.52-0.11-2.38%-- 
Quotes are at least 15-min delayed：2025/09/04 23:07 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.